Actelion is implementing a robust continuity plan in response to the COVID-19 pandemic in order to deliver on our purpose of transforming the lives of patients through innovation. Our focus at Actelion is to develop life-changing medicines for people with serious diseases — often with limited or no options — so they can live their lives more fully, and to support our patient communities in their overall wellness. Especially during a time of uncertainty as we live through this global pandemic, Actelion remains dedicated to this purpose.
In responding to this pandemic, Actelion’s top priorities are the health and safety of our employees and patient access to our medications. We have established a response team that is continually monitoring this public health situation to address potential impact to our employees, our sites and our business.
With employee and community safety in mind, we have implemented new remote work measures for our employees, including restricting business travel and closing offices. Actelion is following World Health Organization (WHO) and Center for Disease Control (CDC) recommendations, as well as national or local guidelines around the world. We are focused on supporting employees through this challenging time and are providing resources and processes if an employee receives a positive COVID-19 test result.
As we announced on March 31st, we are confident in our ability to supply our medicines to patients around the world and currently have ample supply to meet patient needs well into the future, with the exception of Erwinaze which continues to have supply disruption unrelated to COVID-19. Actelion is working closely with the our third-party manufacturers, distributors and other trusted partners to manage the supply chain activities and mitigate any potential disruptions to our product supply as a result of COVID-19. We will continue to monitor any changes in COVID-19 impact to our supply chain.
At Actelion, we are committed to doing our best to ensure our communities can continue to receive the life-changing, often live-saving medicines they need – but our efforts go further. People may need more support as we all navigate the COVID-19 pandemic together, which is why we have ActelionCares and our other specific patient support programs. We know you may have questions and concerns about your medicines or your (or your loved ones’) overall health during this time. ActelionCares has a Patient Support Hotline: 1-833-533-Actelion (5299), with live operators available to support Monday – Friday, 8 AM to 8 PM EST.
We also are committed to being there for people living with serious disease and will provide tips and resources about how to stay healthy during this isolating and challenging time. Now, we need to support each other more than ever.
Actelion is committed to supporting our local communities and patient-focused organizations in COVID-19 relief efforts. To support those individuals and families who need extra help during the COVID-19 pandemic, Actelion has made corporate donations to charitable organizations providing food and medical relief to our local communities in Italy, Philadelphia and the Santa Clara and San Mateo Counties in California. Actelion is also exploring ways to enable employees to give back, like allowing healthcare practitioners employed by Actelion to support local response efforts.
Actelion will continue to monitor the impact of the pandemic across our communities and regularly reevaluate global relief efforts. We are proud to do our part to further support our communities where we live and work.
The COVID-19 pandemic is an unprecedented moment in our history and is affecting each of us and the patient communities we serve across the world in different ways. Our thoughts are with all of those whose lives have been affected by COVID-19. Actelion is committed to providing essential medicines to patients around the world and protecting the health and safety of our employees.
We will get through this together.
Cautionary Notice. This page contains forward-looking statements, including, but not limited to, statements related to continuity plans in light of COVID-19 and availability of product supply and other statements that are not historical facts. These statements are based on Actelion Pharmaceuticals Deutschland GmbH’ current plans, expectations and intentions and actual results could differ materially as a result of the uncertain scale and duration of the COVID-19 pandemic and resulting global economic and financial disruptions and other risks and uncertainties including those described from time to time under the caption “Risk Factors” in Actelion Pharmaceuticals Deutschland GmbH plc’s Annual Report on Form 10-K for the year ended December 31, 2019. The forward-looking statements herein are made only as of the date hereof or as of the dates indicated in the forward-looking statements. Actelion Pharmaceuticals Deutschland GmbH undertakes no obligation to update or supplement any forward-looking statements.
Thank you for visiting actelionpharmaceuticals.de. The site you are about to visit is maintained by a third party who is solely responsible for its content; Actelion Pharmaceuticals Deutschland GmbH is not responsible for the content or privacy practices of any third-party websites. Click Cancel to return or OK to continue.
